| Literature DB >> 27716694 |
Poonam Malhotra Kapoor1, Rohan Magoon1, Rajinder Rawat2, Yatin Mehta3.
Abstract
Goal-directed therapy (GDT) encompasses guidance of intravenous (IV) fluid and vasopressor/inotropic therapy by cardiac output or similar parameters to help in early recognition and management of high-risk cardiac surgical patients. With the aim of establishing the utility of perioperative GDT using robust clinical and biochemical outcomes, we conducted the present study. This multicenter randomized controlled study included 130 patients of either sex, with European system for cardiac operative risk evaluation ≥3 undergoing coronary artery bypass grafting on cardiopulmonary bypass. The patients were randomly divided into the control and GDT group. All the participants received standardized care; arterial pressure monitored through radial artery, central venous pressure (CVP) through a triple lumen in the right internal jugular vein, electrocardiogram, oxygen saturation, temperature, urine output per hour, and frequent arterial blood gas (ABG) analysis. In addition, cardiac index (CI) monitoring using FloTrac™ and continuous central venous oxygen saturation (ScVO2) using PreSep™ were used in patients in the GDT group. Our aim was to maintain the CI at 2.5-4.2 L/min/m2, stroke volume index 30-65 ml/beat/m2, systemic vascular resistance index 1500-2500 dynes/s/cm5/m2, oxygen delivery index 450-600 ml/min/m2, continuous ScVO2 >70%, and stroke volume variation <10%; in addition to the control group parameters such as CVP 6-8 mmHg, mean arterial pressure 90-105 mmHg, normal ABG values, oxygen saturation, hematocrit value >30%, and urine output >1 ml/kg/h. The aims were achieved by altering the administration of IV fluids and doses of inotropes or vasodilators. The data of sixty patients in each group were analyzed in view of ten exclusions. The average duration of ventilation (19.89 ± 3.96 vs. 18.05 ± 4.53 h, P = 0.025), hospital stay (7.94 ± 1.64 vs. 7.17 ± 1.93 days, P = 0.025), and Intensive Care Unit (ICU) stay (3.74 ± 0.59 vs. 3.41 ± 0.75 days, P = 0.012) was significantly less in the GDT group, compared to the control group. The extra volume added and the number of inotropic dose adjustments were significantly more in the GDT group. The two groups did not differ in duration of inotropic use, mortality, and other complications. The perioperative continuation of GDT affected the early decline in the lactate levels after 6 h in ICU, whereas the control group demonstrated a settling lactate only after 12 h. Similarly, the GDT group had significantly lower levels of brain natriuretic peptide, neutrophil gelatinase-associated lipocalin levels as compared to the control. The study clearly depicts the advantage of GDT for a favorable postoperative outcome in high-risk cardiac surgical patients.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27716694 PMCID: PMC5070323 DOI: 10.4103/0971-9784.191552
Source DB: PubMed Journal: Ann Card Anaesth ISSN: 0971-9784
Figure 1The step-wise algorithm followed in the study to allocate, study, and manage the patients receiving goal-directed and conventional therapy
Demographic characteristics of the two groups
| Parameter | Control group ( | GDT group ( | |
|---|---|---|---|
| Age (years) | 61.30±5.60* | 61.17±5.09* | 0.892 |
| Male:female | 42:18 | 40:20 | 0.695 |
| Height (cm) | 160.70±5.18* | 159.98±3.30* | 0.448 |
| Weight (kg) | 72.90±8.79* | 72.97±9.39* | 0.968 |
| EuroSCORE | 4.15±0.84* | 4.13±0.81* | 0.955 |
| CPB (min) | 99.22±6.66* | 99.08±7.63* | 0.919 |
| AOXCL (min) | 57.57±4.00* | 57.50±5.20* | 0.937 |
| Number of grafts | 3.43±0.64* | 3.53±0.79* | 0.695 |
*Standard deviation, P<0.05 is considered significant. GDT: Goal-directed therapy, CPB: Cardiopulmonary bypass, AOXCL: Aortic cross clamping, EuroSCORE: European system for cardiac operative risk evaluation
Heart rate, mean arterial pressure, and central venous pressure in the two groups
| Parameter | Time | Control group ( | GDT group ( | |
|---|---|---|---|---|
| Heart rate | T1 | 69.42±5.02* | 68.17±6.85* | 0.257 |
| T2 | 92.18±7.24* | 93.75±6.51 | 0.215 | |
| T3 | 99.75±8.29* | 100.45±7.69* | 0.633 | |
| T4 | 99.95±8.30* | 102.37±6.13* | 0.072 | |
| T5 | 101.95±8.60* | 103.33±6.10* | 0.312 | |
| T6 | 100.00±6.81* | 100.92±7.11* | 0.473 | |
| MAP | T1 | 89.33±6.98* | 91.57±7.17* | 0.087 |
| T2 | 94.20±6.54* | 94.78±6.85* | 0.634 | |
| T3 | 96.07±6.06* | 97.82±4.16* | 0.068 | |
| T4 | 94.73±6.37* | 96.78±5.65* | 0.065 | |
| T5 | 94.98±5.39* | 97.02±5.91* | 0.052 | |
| T6 | 98.30±6.38* | 100.45±5.59* | 0.052 | |
| CVP | T1 | 6.50±0.93* | 6.08±1.09* | 0.117 |
| T2 | 6.42±0.56* | 6.45±0.77* | 0.753 | |
| T3 | 6.22±0.49* | 6.35±0.58* | 0.175 | |
| T4 | 6.17±0.46* | 6.3±0.80* | 0.182 | |
| T5 | 6.37±0.48* | 6.4±0.58* | 0.736 | |
| T6 | 6.28±0.52* | 6.53±0.87* | 0.059 |
*Standard deviation, P<0.05 is considered significant. T1 (baseline), T2 (sternal closure), T3 (0), T4 (6), T5 (12), T6 (24) h in ICU. ICU: Intensive Care Unit, MAP: Mean arterial pressure, CVP: Central venous pressure, GDT: Goal-directed therapy
Comparison of the outcomes between the control and the goal-directed therapy group
| Parameter | Control group | GDT group | |
|---|---|---|---|
| Average extra volume added | 343.33±62.02* | 376.33±55.23* | 0.003 |
| Number of times inotropes adjusted | 2.77±0.91* | 3.12±0.80* | 0.029 |
| Duration of ventilation (h) | 19.89±3.96* | 18.05±4.53* | 0.025 |
| Duration of inotrope usage (days) | 3.09±0.59* | 2.81±0.94* | 0.063 |
| Length of ICU stay (days) | 3.74±0.59* | 3.41±0.75* | 0.012 |
| Length of hospital stay (days) | 7.94±1.64* | 7.17±1.93* | 0.025 |
| Mortality | 6/60 | 2/60 | 0.272 |
*Standard deviation, P<0.05 is considered significant. Apart from the first two parameters, the n for the outcome measures for the control group was 54 and 58 for the GDT group in view of the mortality. GDT: Goal-directed therapy, ICU: Intensive Care Unit
Comparison of biomarkers between the two groups
| Biomarker | Time | Control group ( | GDT group ( | |
|---|---|---|---|---|
| BNP (pg/mL) | T1 | 152.27±11.60* | 153.72±9.41* | 0.454 |
| T4 | 187.85±13.34* | 184.20±10.24* | 0.095 | |
| T6 | 207.70±28.44* | 198.98±9.33* | 0.026 | |
| NGAL (ng/mL) | T1 | 77.45±12.86* | 81.25±11.29* | 0.088 |
| T4 | 116.95±16.76* | 112.62±9.79* | 0.086 | |
| T6 | 127.45±13.52* | 122.18±8.85* | 0.013 | |
| Lactate (mmol/L) | T1 | 1.00±0.30* | 1.01±0.29* | 0.752 |
| T2 | 2.00±0.60* | 2.03±0.59* | 0.752 | |
| T3 | 2.52±0.40* | 2.38±0.47* | 0.015 | |
| T4 | 4.72±0.43* | 4.51±0.53* | 0.024 | |
| T5 | 5.22±0.64* | 4.14±0.55* | <0.001 | |
| T6 | 3.77±0.31* | 3.23±0.41* | <0.001 |
*Standard deviation, P<0.05 is considered significant). T1 (baseline), T2 (sternal closure), T3 (0), T4 (6), T5 (12), T6 (24) h in ICU. ICU: Intensive Care Unit, GDT: Goal-directed therapy, BNP: Brain natriuretic peptide, NGAL: Neutrophil gelatinase-associated lipocalin
Figure 2The lactate at T1 (baseline), T2 (sternal closure), T3 (0), T4 (6), T5 (12), and T6 (24) h in Intensive Care Unit. The arrow shows the peak in the groups
Figure 3The brain natriuretic peptide, neutrophil gelatinase-associated lipocalin, average hourly urine output at T1, T4, T6, where the rise in brain natriuretic peptide/neutrophil gelatinase-associated lipocalin is clear at T6